Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Tinnitus (tRNS2-tin)

Sponsor
University of Regensburg (Other)
Overall Status
Recruiting
CT.gov ID
NCT02615600
Collaborator
(none)
30
1
1
85
0.4

Study Details

Study Description

Brief Summary

Stimulation of the left and right auditory cortex with daily low-frequency transcranial random noise stimulation (tRNS) is used to modulate the neural pathways involved in chronic tinnitus.

Condition or Disease Intervention/Treatment Phase
  • Device: lf-tRNS
N/A

Detailed Description

Tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. It is a frequent problem which can interfere significantly with the ability to lead a normal life. Tinnitus has been shown to be generated in the brain, as a result of functional reorganization of auditory neural pathways and the central auditory system. These changes are represented by hyper-activity and hyper-synchronicity in the auditory pathway. Treatment remains difficult. Non-invasive brain stimulation methods has shown to be effective in the treatment of chronic tinnitus with moderate effect size. First data suggest the use of transcranial random noise stimulation (tRNS) over both auditory cortices as new and highly effective treatment. Low-frequency (lf; <100Hz) tRNS might be highly effective in tackling hyper-synchronised cell assemblies. Daily lf-tRNS (2 weeks) will be examined with regard to feasibility, safety and clinical efficacy in patients suffering from chronic tinnitus in an one-arm pilot trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Patients With Chronic Tinnitus
Study Start Date :
Nov 1, 2015
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: lf-tRNS

Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4

Device: lf-tRNS
Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4

Outcome Measures

Primary Outcome Measures

  1. number of treatment responders [week 12]

    response: tinnitus questionnaire total score reduction of at least 5 points, contrast baseline versus end of treatment (week 12)

Secondary Outcome Measures

  1. change in tinnitus questionnaire [week 2, week 4, week 12]

    change in tinnitus questionnaire

  2. change in tinnitus handicap inventory [week 2, week 4, week 12]

    change in tinnitus handicap inventory

  3. change in tinnitus numeric rating scales [week 2, week 4, week 12]

    change in tinnitus numeric rating scales

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  • diagnosis of bothersome, subjective chronic tinnitus

  • diagnosis: duration of tinnitus more than 6 months

Exclusion criteria:
  • objective tinnitus

  • irregular head shap below the electrodes

  • eczema on the head

  • treatable cause of the tinnitus

  • involvement in other treatments for tinnitus at the same time

  • clinically relevant psychiatric comorbidity

  • clinically relevant unstable internal or neurological comorbidity

  • history of or evidence of significant brain malformation or neoplasm, head injury

  • cerebral vascular events

  • neurodegenerative disorder affecting the brain or prior brain surgery

  • metal objects in and around body that can not be removed

  • pregnancy

  • alcohol or drug abuse

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Regensburg - Deptartment of Psychiatry Regensburg Germany 93053

Sponsors and Collaborators

  • University of Regensburg

Investigators

  • Principal Investigator: Berthold Langguth, University of Regensburg

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Berthold Langguth, MD, Ph.D., M.D., Ph.D., University of Regensburg
ClinicalTrials.gov Identifier:
NCT02615600
Other Study ID Numbers:
  • Uni-Reg-tRNS02
First Posted:
Nov 26, 2015
Last Update Posted:
Jan 20, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Berthold Langguth, MD, Ph.D., M.D., Ph.D., University of Regensburg
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2021